Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.80 |
| ▸ | PDE4A | P27815 | 6/20 | 0.80 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.80 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985307 | 0.90 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL6878175 | 0.90 | PDE4B (0.85) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL1164280 | 0.89 | PDE4B (0.80) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL7336155 | 0.89 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL7362694 | 0.88 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL6877187 | 0.88 | PDE4B (0.82) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL7361935 | 0.88 | PDE4B (0.94) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL7334333 | 0.87 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL7339491 | 0.87 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CCYP2B6 | |
| SCHEMBL15270505 | 0.87 | PDE4D (1.00) | PDE4BPDE4DPDE4APDE4CCYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245038-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| EP-2247294-B1 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | BASILEA PHARMACEUTICA AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2247294-A2 | MACROLIDES FOR TREATING DISEASES MEDIATED THROUGH PDE INHIBITION | Basilea Pharmaceutica AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-2245038-A1 | NEW MACROLIDES AND THEIR USE | Basilea Pharmaceutica AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4D 6/4885PDE4A 1/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4B 2412/4885PDE4D 2679/4885PDE4A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.